Drugs / Yixin Powder
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT07378228 | Jul 2023 → Jun 2024 | coronary artery disorder | Xikun Li | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Yixin Powder | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07378228 ↗ |
| Modality | Traditional medicine (herbal / TCM) | “A traditional Chinese herbal formula composed of red ginseng (5 g), pseudo-ginseng powder (3 g), dragon's blood (1 g), leech (3 g), succinite (3 g), Chinese hawthorn fruit (10...” NCT07378228 ↗ |
| Route | Oral | “Administered orally at a total daily dose of 30 g” NCT07378228 ↗ |